Figure 3.
Treatment course of DR CLL. TAs refer to cBTKis, ncBTKis, BCL2is, and/or PI3Kis. Other treatments included bispecific antibody, BTK degrader, anti-CD19 mAb, anti-CD20 mAb, anti-CD52 mAb, and CIT. Patient 30 was on a BCL2i for 26 days before developing DR disease. DLBCL, diffuse large B-cell lymphoma; mAb, monoclonal antibody; PI3Ki, phosphoinositide 3-kinase inhibitor; TA, targeted agent.

Treatment course of DR CLL. TAs refer to cBTKis, ncBTKis, BCL2is, and/or PI3Kis. Other treatments included bispecific antibody, BTK degrader, anti-CD19 mAb, anti-CD20 mAb, anti-CD52 mAb, and CIT. Patient 30 was on a BCL2i for 26 days before developing DR disease. DLBCL, diffuse large B-cell lymphoma; mAb, monoclonal antibody; PI3Ki, phosphoinositide 3-kinase inhibitor; TA, targeted agent.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal